Abstract: Objective: The relative preventative efficacy of amiodarone and lidocaine for ventricular fibrillation (VF) after release of an aortic cross-clamp (ACC) during open heart surgery has not been determined. This meta-analysis was designed to systematically evaluate the influence of amiodarone, lidocaine, or placebo on the incidence of VF after ACC. Methods: Prospective randomized controlled trials (RCTs) that compared the VF-preventative effects of amiodarone with lidocaine, or amiodarone or lidocaine with placebo were included. PubMed, EMBASE, and the Cochrane Library were searched for relevant RCTs. Fixed or randomized effect models were applied according to the heterogeneity of the data from the selected studies. Results: We included eight RCTs in the analysis. Pooled results suggested that the preventative effects of amiodarone and lidocaine were comparable (relative risk (RR)=1.12, 95% confidence interval (CI): 0.70 to 1.80, P=0.63), but both were superior to the placebo (amiodarone, RR=0.71, 95% CI: 0.51 to 1.00, P=0.05; lidocaine, RR=0.63, 95% CI: 0.46 to 0.88, P=0.006). The percentage of patients requiring electric defibrillation counter shocks (DCSs) did not differ significantly among patients administered amiodarone (RR=0.21, 95% CI: 0.04 to 1.19, P=0.08), lidocaine (RR=2.44, 95% CI: 0.13 to 44.02, P=0.55), or the placebo (RR=0.56, 95% CI: 0.25 to 1.25, P=0.16). Conclusions: Amiodarone and lidocaine are comparably effective in preventing VF after ACC, but the percentage of patients who subsequently require DCSs does not differ among those administered amiodarone, lidocaine, or placebo.

胺碘酮和利多卡因对开胸心脏手术中再灌注性室颤预防效果的随机对照试验荟萃分析

[1]American Heart Association, 1992. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. JAMA, 268(16):2171-2183.

[2]American Heart Association, 2000. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. Circulation, 102(8 Suppl.):I112-I128.

[3]Ayoub, C.M., Sfeir, P.M, Bou-Khalil, P., et al., 2009. Prophylactic amiodarone versus lidocaine for prevention of reperfusion ventricular fibrillation after release of aortic cross-clamp. Eur. J. Anaesthesiol., 26(12):1056-1060.

[4]Baraka, A., Hirt, N., Dabbous, A., et al., 1993. Lidocaine cardioplegia for prevention of reperfusion ventricular fibrillation. Ann. Thorac. Surg., 55(6):1529-1533.

[5]Baraka, A., Kawkabani, N., Dabbous, A., et al., 2000. Lidocaine for prevention of reperfusion ventricular fibrillation after release of aortic cross-clamping. J. Cardiothor. Vas. An., 14(5):531-533.

[6]Baravelli, M., Cattaneo, P., Rossi, A., et al., 2010. Low-risk profile for malignant ventricular arrhythmias and sudden cardiac death after surgical ventricular reconstruction. Pacing Clin. Electrophysiol., 33(9):1054-1062.

[7]Chevalier, P., Timour, Q., Morel, E., et al., 2012. Chronic oral amiodarone but not dronedarone therapy increases ventricular defibrillation threshold during acute myocardial ischemia in a closed-chest animal model. J. Cardiovasc. Pharmacol., 59(6):523-528.

[8]Doherty, P.W., McLaughlin, P.R., Billingham, M., et al., 1979. Cardiac damage produced by direct current countershock applied to the heart. Am. J. Cardiol., 43(2):225-232.

[9]Dorian, P., Cass, D., Schwartz, B., et al., 2002. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N. Engl. J. Med., 347(12):955.

[10]Fiore, A.C., Naunheim, K.S., Taub, J., et al., 1990. Myocardial preservation using lidocaine blood cardioplegia. Ann. Thorac. Surg., 50(5):771-775.

[11]Furlan, A.D., Malmivaara, A., Chou, R., et al., 2015. 2015 updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine, 40(21):1660-1673.

[12]Geissler, H.J., Schlensak, C., Sudkamp, M., et al., 2009. Heart valve surgery today: indications, operative technique, and selected aspects of postoperative care in acquired valvular heart disease. Dtsch. Arztebl. Int., 106(13):224-233.

[13]Ghavidel, A.A., Nabavi, S., Haghjoo, M., et al., 2013. Amiodarone versus lidocaine for the prevention of reperfusion ventricular fibrillation: a randomized clinical trial. ARYA Atheroscler., 1:343-349.

[14]Hippelainen, M.J., Tuppurainen, T.T., Huttunen, K.T., 1994. Reperfusion ventricular fibrillation and electric countershocks during coronary artery bypass operations-association with postoperative CK-MB release. J. Thorac. Cardiovasc. Surg., 28(2):73-78.

[15]Kirlangitis, J., Middaugh, R., Knight, R., et al., 1990. Comparison of bretylium and lidocaine in the prevention of ventricular fibrillation after aortic cross-clamp release in coronary artery bypass surgery. J. Cardiothorac. Anesth., 4(5):582-587.

[16]Komori, S., Li, B., Matsumura, K., et al., 1999. Antiarrhythmic effect of magnesium sulfate against occlusion-induced arrhythmias and reperfusion-induced arrhythmias in anesthetized rats. Mol. Cell Biochem., 199(1-2):201-208.

[17]Leeuwenburgh, B.P., Versteegh, M.I., Maas, J.J., et al., 2008. Should amiodarone or lidocaine be given to patients who arrest after cardiac surgery and fail to cardiovert from ventricular fibrillation? Interact. Cardiovasc. Thorac. Surg., 7(6):1148-1151.

[18]Levine, J.H., Massumi, A., Scheinman, M.M., et al., 1996. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias intravenous amiodarone multicenter trial group. J. Am. Coll. Cardiol., 27(1):67-75.

[19]Liu, X.B., Jiang, J.B., Zhou, Q.J., et al., 2015. Evaluation of the safety and efficacy of transcatheter aortic valve implantation in patients with a severe stenotic bicuspid aortic valve in a Chinese population. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 16(3):208-214.

[20]Marathe, S.P., Talwar, S., 2015. Surgery for transposition of great arteries: a historical perspective. Ann. Pediatr. Cardiol., 8(2):122-128.

[21]Mauermann, W.J., Pulido, J.N., Barbara, D.W., et al., 2012. Amiodarone versus lidocaine and placebo for the prevention of ventricular fibrillation after aortic crossclamping: a randomized, double-blind, placebo-controlled trial. J. Thorac. Cardiovasc. Surg., 144(5):1229-1234.

[22]Mery, C.M., Kane, L.C., 2017. The ACGME fellowship in congenital cardiac surgery: the graduates’ perspective. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Ann., 20:70-76.

[23]Moher, D., Liberati, A., Tetzlaff, J., et al., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med., 151(4):264-269.

[24]Nayeem Ul, H., Dar, A.M., Wani, M.L., et al., 2013. A comparative study on the effect of amiodarone and metaprolol for prevention of arrythmias after open heart surgery. Int. Cardiovasc. Res. J., 7(1):1-4.

[25]Onk, O.A., Erkut, B., 2015. Is the preoperative administration of amiodarone or metoprolol more effective in reducing atrial fibrillation: after coronary bypass surgery? Medicine (Baltimore), 94(41):e1576.

[26]Papakonstantinou, N.A., Baikoussis, N.G., Dedeilias, P., et al., 2017. Cardiac surgery or interventional cardiology? Why not both? Let’s go hybrid. J. Cardiol., 69(1):46-56.

[27]Patil, K.D., Halperin, H.R., Becker, L.B., 2015. Cardiac arrest: resuscitation and reperfusion. Circ. Res., 116(12):2041-2049.

[28]Petrovic, T., Adnet, F., Lapandry, C., 1998. Successful resuscitation of ventricular fibrillation after low-dose amiodarone. Ann. Emerg. Med., 32(4):518-519.

[29]Samantaray, A., Chandra, A., Panigrahi, S., 2010. Amiodarone for the prevention of reperfusion ventricular fibrillation. J. Cardiothorac. Vasc. Anesth., 24(2):239-243.

[30]Schluter, T., Baum, H., Plewan, A., et al., 2001. Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage. Clin. Chem., 47(3):459-463.

[31]Shake, J.G., Pronovost, P.J., Whitman, G.J., 2013. Cardiac surgical ICU care: eliminating ‘preventable’ complications. J. Card. Surg., 28(4):406-413.

[32]Somberg, J.C., Bailin, S.J., Haffajee, C.I., et al., 2002. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am. J. Cardiol., 90(8):853-859.

[33]Vaziri, M.T.M., Jouibar, R., Akhlagh, S.H.A., et al., 2010. The effect of lidocaine and magnesium sulfate on prevention of ventricular fibrillation in coronary artery bypass grafting surgery. Iran Red Crescent Med. J., 12(3):298-301.

[34]Verrier, E.D., Mack, M.J., 2015. Viewpoint: transitions in cardiac surgery and interventional cardiology team mates or rivals? Heart, 101(5):346-348.

[35]Wenger, T.L., Lederman, S., Starmer, C.F., et al., 1984. A method for quantitating antifibrillatory effects of drugs after coronary reperfusion in dogs: improved outcome with bretylium. Circulation, 69(1):142-148.

[36]Wu, L., Jin, Q., Zhang, N., et al., 2011. The effects of acute amiodarone on short-and long-duration ventricular defibrillation threshold in canines. J. Cardiovasc. Pharmacol., 58(4):432-438.

[37]Wyman, M.G., Wyman, R.M., Cannom, D.S., et al., 2004. Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine. Am. J. Cardiol., 94(5):545-551.

[38]Yamaguchi, H., Weil, M., Tang, W., et al., 2002. Myocardial dysfunction after electrical defibrillation. Resuscitation, 54(3):289-296.

[39]Yeh, S.T., Aune, S.E., Wilgus, T.A., et al., 2013. Hyperoxemic reperfusion after prolonged cardiac arrest in a rat cardiopulmonary bypass resuscitation model. Resuscitation, 84(1):114-120.

[40]Yilmaz, M., Aydin, U., Arslan, Z.I., et al., 2014. The effect of lidocaine and amiodarone on prevention of ventricular fibrillation in patients undergoing coronary artery bypass grafting. Heart Surg. Forum., 17(5):245-249.

[41]Zhan, H.T., Purcell, S.T., Bush, R.L., 2015. Preoperative optimization of the vascular surgery patient. Vasc. Health Risk Manag., 11:379-385.

[42]Zoerner, F., Semenas, E., 2014. Resuscitation with amiodarone increases survival after hemorrhage and ventricular fibrillation in pigs. J. Trauma Acute Care Surg., 76(6):1402-1408.